dr. oxnard on detecting resistance mechanisms after treatment with osimertinib
Published 7 years ago • 771 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:26
dr. oxnard on the role of osimertinib in the tatton trial for lung cancer
-
5:52
treatment of egfr nsclc after osimertinib
-
2:04
acquired resistance to osimertinib in t790m-positive nsclc
-
1:44
dr. oxnard on delaying second-line treatment in egfr-mutant lung cancer
-
5:46
resistance mechanisms in egfr nsclc
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc
-
1:41
dr. goldberg on resistance to osimertinib for nsclc
-
1:06
dr. carbone on acquired resistance to osimertinib in nsclc
-
1:43
dr. padda on overcoming resistance to osimertinib in egfr nsclc
-
2:23
dr. zhu on primary resistance to osimertinib in egfr-mutant nsclc
-
5:29
osimertinib for the t790m resistance mutation
-
8:55
global perspectives on use of osimertinib in egfr nsclc
-
0:46
dr. geoffrey r. oxnard treating patients who have become resistant to egfr-inhibitors
-
2:12
dr. oxnard discusses the circulating cell-free genome atlas study
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:37
sangeetha palakurthi on strategies for managing resistance to osimertinib in patients with nsclc
-
5:45
osimertinib in t790m-mutant lung cancer